Anti-IgE therapy versus allergen-specific immunotherapy for food allergy: weighing the pros and cons

With the recent FDA approval of the anti-IgE biologic, omalizumab, in 2024 for the treatment of food allergy, it is critical to consider the advantages and disadvantages of anti-IgE and allergen-specific immunotherapies (AITs) to help determine optimal patient care. Several AITs have been studied fo...

詳細記述

書誌詳細

主要な著者:	Michael D. Kulis, Jessica R. Humphrey, James W. Krempski, Edwin H. Kim, Johanna M. Smeekens
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2025-07-01
シリーズ:	Frontiers in Immunology
主題:	omalizumab allergy immunotherapy oral immunotherapy sublingual immunotherapy epicutaneous immunotherapy IgE
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1617153/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!